市場調査レポート
商品コード
1422960
経カテーテル肺動脈弁市場:技術別、原材料別、用途別、エンドユーザー別、地域別、2024-2032年Transcatheter Pulmonary Valve Market by Technology, Raw Material, Application, End User, and Region 2024-2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
経カテーテル肺動脈弁市場:技術別、原材料別、用途別、エンドユーザー別、地域別、2024-2032年 |
出版日: 2024年01月30日
発行: IMARC
ページ情報: 英文 144 Pages
納期: 2~3営業日
|
経カテーテル肺動脈弁の世界市場規模は、2023年に8,830万米ドルに達しました。今後、IMARC Groupは、市場が2032年までに1億8,110万米ドルに達し、2024年から2032年の間に8.06%の成長率(CAGR)を示すと予測しています。さまざまな心血管疾患(CVDs)の発生率の増加、広範な研究開発(R&D)活動、高齢者人口の増加が、市場を牽引する主な要因のいくつかです。
経カテーテル肺動脈弁とは、ウシ、ブタ、ヒトの心臓組織から作られた人工弁のことです。開腹手術よりも切開回数が少なく、回復も早いため、漏れたり狭くなったりした肺動脈弁を交換して血流を改善するために広く使用されています。これらの弁は、細い柔軟な管(カテーテル)を通して太い血管に挿入され、低侵襲(MI)手術が行われます。経カテーテル的肺動脈弁置換術は、痛みや回復期間が短く、合併症のリスクを下げながら症状を改善することができます。また、血流を回復させ、胸痛、息切れ、失神、疲労といった大動脈弁狭窄症の徴候や症状を軽減するのにも役立ちます。その結果、これらのバルブは、心臓異常、肺逆流、無気脈症、狭窄症、動脈瘤などに幅広く応用されています。
リウマチ性心疾患、高血圧性心疾患、脳血管疾患、炎症性心疾患など、さまざまな心血管疾患(CVD)の発生率が世界中で上昇していることが、市場成長を促進する主な要因の1つです。これに伴い、高齢者人口の増加、重度の大動脈弁狭窄症や僧帽弁および三尖弁閉鎖不全症に関連する変性異常の有病率の増加が、市場成長に好影響を与えています。さらに、小児の経カテーテル肺治療に広く製品が採用されていることも、市場の成長に寄与しています。これは主に、肺動脈狭窄症、閉鎖不全症、ファロー四徴症、その他の関連疾患の頻度が増加しているためであり、効果的な治療オプションとして製品採用が促進されています。これとは別に、経カテーテル肺動脈弁置換術(TPVR)における人工知能(AI)の統合は、術前計画、危険因子の特定、診断および臨床的意思決定の強化を支援するため、市場成長に弾みをつけています。また、バルーン拡張技術に対する需要の高まりは、プロセスがより迅速かつ簡素化され、結果の精度と精度が高いことから、市場成長にプラスの影響を与えています。このほか、ニチノール製の自己拡張型大動脈弁システムであるヒドラ大動脈弁の発売は、弁の正確な配置を可能にし、同所への配置を確実にするため、市場成長を後押ししています。革新的な心臓弁への需要の高まり、高血圧症例の増加、ヘルスケア産業の成長、消費者の支出能力の上昇、広範な研究開発(R&D)活動、効率的な経カテーテル肺動脈弁を開発するための様々な政府イニシアチブの実施など、その他の要因によって、市場の見通しは明るいと予想されます。
The global transcatheter pulmonary valve market size reached US$ 88.3 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 181.1 Million by 2032, exhibiting a growth rate (CAGR) of 8.06% during 2024-2032. The increasing incidence of various cardiovascular diseases (CVDs), extensive research and development (R&D) activities, and the rising geriatric population represent some of the key factors driving the market.
A transcatheter pulmonary valve refers to an artificial valve made from cow, pig, or human heart tissue. It is widely used to replace leaky or narrowed pulmonary valves to improve blood flow, with fewer incisions and faster recovery than open surgery. These valves are inserted through a thin, flexible tube (catheter) into a large blood vessel involving a minimally invasive (MI) procedure. Transcatheter pulmonary valve replacement involves less pain and a shorter recovery period and helps in improving symptoms while lowering the risk of medical complications. It also helps to restore blood flow and reduce the signs and symptoms of aortic valve stenosis, such as chest pain, shortness of breath, fainting, and fatigue. As a result, these valves find extensive applications in cardiac anomaly, pulmonary regurgitation, atresia, stenosis, and truncus arteriosus.
The rising incidences of various cardiovascular diseases (CVDs), such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases across the globe, are among the key factors driving the market growth. In line with this, the rising geriatric population and increasing prevalence of degenerative abnormalities associated with severe aortic stenosis and mitral and tricuspid regurgitation are favoring the market growth. Moreover, the widespread product adoption in the treatment of pediatric transcatheter pulmonary is contributing to the market growth. This can be primarily attributed to the increasing frequency of pulmonary stenosis, atresia, tetralogy of Fallot, and other related disorders, which is facilitating the product adoption as an effective treatment option. Apart from this, the integration of artificial intelligence (AI) in the transcatheter pulmonary valve replacement (TPVR) procedure, as it assists in pre-procedural planning, identifying risk factors, and enhancing diagnosis and clinical decision-making, is providing an impetus to the market growth. Additionally, the increasing demand for balloon-expanded technology as it involves a faster and simpler process and offers high accuracy and precision of the result is positively influencing the market growth. Besides this, the launch of the hydra aortic valve, which is a self-expanding supra-annular aortic system made of nitinol that allows precise placement of the valve and ensures orthotopic deployment, is propelling the market growth. Other factors, including growing demand for innovative heart valves, an increasing number of hypertension cases, escalating growth in the healthcare industry, rising expenditure capacities of consumers, extensive research and development (R&D) activities, and the implementation of various government initiatives to develop efficient transcatheter pulmonary valves, are anticipated to create a positive outlook for the market.
IMARC Group provides an analysis of the key trends in each segment of the global transcatheter pulmonary valve market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, raw material, application, and end user.
Balloon-Expanded Transcatheter Valve
Self-Expanded Transcatheter Valve
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the technology. This includes balloon-expanded transcatheter valve and self-expanded transcatheter valve. According to the report, balloon-expanded transcatheter valve represented the largest segment.
Tissue Engineered
Synthetic
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the raw material. This includes tissue engineered and synthetic. According to the report, tissue engineered represented the largest segment.
Tetralogy of Fallot
Cardiac Anomaly
Pulmonary Atresia
Pulmonary Stenosis
Pulmonary Regurgitation
Truncus Arteriosus
Others
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the application. This includes tetralogy of fallot, cardiac anomaly, pulmonary atresia, pulmonary stenosis, pulmonary regurgitation, truncus arteriosus, and others. According to the report, tetralogy of fallot represented the largest segment.
Adult
Pediatric
The report has provided a detailed breakup and analysis of the transcatheter pulmonary valve market based on the end user. This includes adult and pediatric. According to the report, adult represented the largest segment.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others);Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for transcatheter pulmonary valve. Some of the factors driving the North America transcatheter pulmonary valve market included the rising geriatric population, growing demand for innovative heart valves, and various technological advancements.
The report has also provided a comprehensive analysis of the competitive landscape in the global transcatheter pulmonary valve market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, Artivion Inc., Boston Scientific Corporation, Braile Biomedica, Colibri Heart Valve LLC, Edwards Lifesciences Corporation, JenaValve Technology Inc., Labcor Laboratorios Ltda., Medtronic plc, Venus Medtech (Hangzhou) Inc., etc.